DaShenLin Pharmaceutical Group Co., Ltd.

SHSE:603233 주식 보고서

시가총액: CN¥17.4b

DaShenLin Pharmaceutical Group 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Guoqiang Ke

최고 경영자

CN¥2.3m

총 보상

CEO 급여 비율n/a
CEO 임기5.8yrs
CEO 소유권0.02%
경영진 평균 재임 기간데이터 없음
이사회 평균 재임 기간1.8yrs

최근 관리 업데이트

Recent updates

Take Care Before Diving Into The Deep End On DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233)

Sep 30
Take Care Before Diving Into The Deep End On DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233)

DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Sep 03
DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

DaShenLin Pharmaceutical Group (SHSE:603233) May Have Issues Allocating Its Capital

Aug 20
DaShenLin Pharmaceutical Group (SHSE:603233) May Have Issues Allocating Its Capital

Not Many Are Piling Into DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Stock Yet As It Plummets 27%

Jun 17
Not Many Are Piling Into DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Stock Yet As It Plummets 27%

Does DaShenLin Pharmaceutical Group (SHSE:603233) Have A Healthy Balance Sheet?

Jun 09
Does DaShenLin Pharmaceutical Group (SHSE:603233) Have A Healthy Balance Sheet?

Are Investors Undervaluing DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) By 30%?

May 21
Are Investors Undervaluing DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) By 30%?

Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) Earnings

May 06
Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) Earnings

Investors Could Be Concerned With DaShenLin Pharmaceutical Group's (SHSE:603233) Returns On Capital

Apr 09
Investors Could Be Concerned With DaShenLin Pharmaceutical Group's (SHSE:603233) Returns On Capital

Lacklustre Performance Is Driving DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Low P/E

Mar 17
Lacklustre Performance Is Driving DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Low P/E

CEO

Guoqiang Ke (42 yo)

5.8yrs

테뉴어

CN¥2,308,800

보상

Mr. Guoqiang Ke is General Manager of DaShenLin Pharmaceutical Group Co., Ltd. from February 28, 2019 and serves as DIrector since February 03, 2023. He was Deputy General Manager of DaShenLin Pharmaceutic...


이사회 구성원

이름위치테뉴어보상소유권
Guoqiang Ke
GM & Director1.8yrsCN¥2.31m0.025%
CN¥ 4.3m
Qun Fei Tan
Deputy GM & Director1.8yrsCN¥2.05m0.024%
CN¥ 4.1m
Zhi Hui Chen
Chairman of Supervisory Board & Deputy Director of Human Resources Department - Guangdong Provinceno data데이터 없음0.012%
CN¥ 2.1m
Yun Feng Ke
Chairman of the Boardno dataCN¥2.49m21.3%
CN¥ 3.7b
Guo Liu
Independent Directorno dataCN¥73.40k데이터 없음
Zu Yao Su
Independent Directorno dataCN¥80.00k데이터 없음
Jie Li
Directorno data데이터 없음데이터 없음
Li Ping Lu
Independent Directorno dataCN¥80.00k데이터 없음
Jinshu Shi
Staff Supervisorno data데이터 없음0.00055%
CN¥ 95.8k
Wensheng Chen
Supervisor1.8yrs데이터 없음데이터 없음

1.8yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 이사회: 603233 의 이사회경험(평균 재직 기간 1.8 년)으로 간주되지 않으므로 새 이사회가 필요합니다.